A specialist lab facility tailored to the commercialisation of life sciences on Newcastle Helix has welcomed new tenants as the ecosystem continues to grow.
The Biosphere is a high-quality building with office space and both chemistry and biology laboratories available. The new tenants, Biosignatures and Cognassist, add to the already impressive number of innovative life sciences organisations in the facility.
AI biotechnology company, Biosignatures is one new face at The Biosphere having raised £3.5m in funding last year to develop its unique diagnostic technology. Its machine learning…
Cambridge, UK, 16 March 2020: TTP plc (TTP), a leading independent technology and product development company, today announced it has established a partnership with NHS Highland and The University of the Highlands and Islands, to use clinical data interpretation and machine learning algorithms to predict which patients with atrial fibrillation (AF) are able to be successfully treated using electrical cardioversion (ECV).
AF is a common heart condition, causing an abnormally fast heart rate and irregular rhythm, which can lead to significant morbidity (e.g. stroke, heart failure), and…
AMSBIO announce the availability of recombinant proteins and antibodies for detection of Coronavirus (COVID-19) and related RNA viruses.Historically strains of Coronavirus able to infect humans (HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoVHKU1) were not highly pathogenic and only caused mild respiratory illness. By comparison more recent strains - SARS-CoV, MERS-CoV and COVID-19 that emerged in Wuhan, China at the end of 2019 are highly pathogenic resulting in large scale pandemics.Coronaviruses are a group of enveloped positive-stranded RNA viruses, which contains four…
AMSBIO offers a Skeletal Muscle Differentiation kit that enables you to differentiate human pluripotent stem cells to skeletal muscle myotubes with high yields, without cell sorting or genetic manipulation. Myotubes are contractile, express typical muscle markers that show striated sarcomeres.Until recently methods of studying muscular disease and potential therapies were dependent on invasive muscle biopsies to produce limited batches of primary cells. Use of primary cells presents challenges, not only in the collection process but also related to inconsistencies in cell growth, behaviour…
If you work in the biotech, pharma, medical or related scientific area, and have marketing goals for 2020 - we would be grateful if you could fill out our 1 min marketing survey.
Onyva The Agency is looking for your expert input on its (very) short survey, to help serve the sector better. The poll includes entry into an optional prize draw of £100 worth of office treats. Anonymized results will be sent to participants.
Please follow this link:
https://onyva-agency.com/2020/01/31/lifesciencemarketing-survey-short/
Cambridge 05 March 2020: Introduced by the Babraham Research Campus in 2018, the Accelerate@Babraham initiative supports ambitious early stage life science ventures within the active Babraham Research Campus community. As part of this initiative StartUP@Babraham is a competition specifically to support ideas and/or companies that are pre-seed to seed stage (below £500k investment). Each year, via a rigorous application and selection process, a handful of early stage life sciences enterprises are selected to take part in this bio-entrepreneurial programme. In addition to a place on the…
A Newcastle medtech company has secured nearly £250,000 in funding from Innovate UK to further its research into the impact of genetics on implants.
Based in The Biosphere on Newcastle Helix, ExplantLab combines extensive medical, bioengineering and surgical knowledge to further understand explants (implants that have been removed from the body). Having opened last year with both chemistry and biology laboratories, The Biosphere is already close to 50 per cent full and is home to a host of innovative life sciences companies.
The Innovate UK funding will allow ExplantLab to develop its machine…
Westbury, NY – Mar. 3, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, announced that it is now providing same-day delivery of fresh blood, LEUKOMAX® leukopaks and buffy coats from normal and disease-state donors to cell and gene therapy researchers in the UK. BioIVT is also shipping these products overnight to certain EU locations.
This service is being offered through BioIVT’s CTLS donor center in London, which sees more than 2,500 donors per year. Since BioIVT acquired CTLS in 2018, it has expanded CTLS’ capabilities by introducing…
Cambridge, UK, 2nd March 2020: CN Bio Innovations (“CN Bio”), a leading cell culture company that has developed organ-on-chip laboratory instruments to improve the accuracy and efficiency of drug discovery, today announced it has raised $9 million USD (circa £6.9 million GBP) investment, led by CITIC Securities Investment Co., Ltd., and supported by existing investor CN Innovations Holdings Ltd.
The funding will be used to support commercial development and strengthen CN Bio’s position in its key market, the US, whilst also expanding operations across Europe. This funding will help drive…